Vaishali Pharma Limited — Others, 06-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Vaishali Pharma Limited reported that there were no deviations or variations in the utilization of funds from the issuance of equity shares through warrant conversions for the quarter ending December 31, 2024. A total of ₹30.46 crore was raised on July 16, 2024, and the Audit Committee confirmed the proper use of these funds for intended purposes, reflecting effective governance. This clarity on fund utilization could enhance investor confidence, indicating a disciplined approach to capital management and potentially fostering a positive outlook among stakeholders.